AbbVie to Acquire Pharmacyclics for $21 Billion
AbbVie’s acquisition of Pharmacyclics establishes the combined company as an emerging leader in hematological oncology.
AbbVie and Pharmacyclics announced on March 4 that AbbVie will acquire Pharmacyclics and its flagship asset Imbruvica (ibrutinib), a treatment for hematologic malignancies, for approximately $21 billion.
Under the terms of the transaction, AbbVie will pay $261.25 per share comprised of a mix of cash and AbbVie equity. The boards of directors of both companies have approved the transaction.
According to an AbbVie statement, the acquisition accelerates the company’s clinical and commercial presence in oncology.
Imbruvica is a Bruton's tyrosine kinase inhibitor approved for use in four indications to treat three different types of blood cancers including chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's macroglobulinemia.
Source: AbbVie
EMA Recommends Imfinzi-Based Perioperative Regimen for Treating Resectable NSCLC
March 10th 2025The committee’s recommendation is based on results from a Phase III trial in which Imfinzi demonstrated a reduced risk of recurrence, progression, or death by 32% compared to neoadjuvant chemotherapy alone.
International Women’s Day 2025: A Promising Future for Gender Diversity in Pharma
March 8th 2025In an interview with BioPharm International®, Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
